<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Oncol Lett</journal-id><journal-id journal-id-type="iso-abbrev">Oncol Lett</journal-id><journal-id journal-id-type="publisher-id">OL</journal-id><journal-title-group><journal-title>Oncology Letters</journal-title></journal-title-group><issn pub-type="ppub">1792-1074</issn><issn pub-type="epub">1792-1082</issn><publisher><publisher-name>D.A. Spandidos</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29399191</article-id><article-id pub-id-type="pmc">5774520</article-id><article-id pub-id-type="doi">10.3892/ol.2017.7482</article-id><article-id pub-id-type="publisher-id">OL-0-0-7482</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>Effects of flurbiprofen on serum level of interleukin-6, prostacyclin and corticosteroid A2 in patients with bone metastases of cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Yin</surname><given-names>Yanwei</given-names></name><xref ref-type="aff" rid="af1-ol-0-0-7482"/></contrib><contrib contrib-type="author"><name><surname>Yi</surname><given-names>Yusheng</given-names></name><xref ref-type="aff" rid="af1-ol-0-0-7482"/><xref rid="c1-ol-0-0-7482" ref-type="corresp"/></contrib><contrib contrib-type="author"><name><surname>Yu</surname><given-names>Junmin</given-names></name><xref ref-type="aff" rid="af1-ol-0-0-7482"/></contrib><contrib contrib-type="author"><name><surname>Sun</surname><given-names>Xiuming</given-names></name><xref ref-type="aff" rid="af1-ol-0-0-7482"/></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Chuansheng</given-names></name><xref ref-type="aff" rid="af1-ol-0-0-7482"/></contrib><contrib contrib-type="author"><name><surname>Xu</surname><given-names>Fenghe</given-names></name><xref ref-type="aff" rid="af1-ol-0-0-7482"/></contrib></contrib-group><aff id="af1-ol-0-0-7482">Department of Pain Treatment, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266003, P.R. China</aff><author-notes><corresp id="c1-ol-0-0-7482"><italic>Correspondence to</italic>: Dr Yusheng Yi, Department of Pain Treatment, The Affiliated Hospital of Qingdao University, 16 Jiangsu Road, Qingdao, Shandong 266003, P.R. China, E-mail: <email>tiyv04@163.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>2</month><year>2018</year></pub-date><pub-date pub-type="epub"><day>23</day><month>11</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>23</day><month>11</month><year>2017</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>15</volume><issue>2</issue><fpage>1545</fpage><lpage>1548</lpage><history><date date-type="received"><day>25</day><month>7</month><year>2017</year></date><date date-type="accepted"><day>14</day><month>11</month><year>2017</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; Yin et al.</copyright-statement><copyright-year>2018</copyright-year><license license-type="open-access"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivs License</ext-link>, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.</license-p></license></permissions><abstract><p>The present study aimed to investigate the effects of flurbiprofen on serum level of interleukin-6 (IL-6), prostacyclin (PGI2) and corticosteroid A2 (TXA2) in patients with bone metastases of cancer. A total of 210 patients with bone metastasis of cancer were randomly divided into two groups: Flurbiprofen axetil analgesia group (group A) and dezocine analgesia group (group B), 105 cases in each group. The analgesic effect was evaluated using visual analogue scale (VAS) scoring system at 1, 12, 24 and 48 h after treatment. Serum levels of IL-6, PGI2 and TXA2 at 12 and 24 h after treatment were detected using double-antibody sandwich enzyme-linked immunosorbent assay. No significant differences in VAS scores were found between the two groups at 1, 12, 24 and 48 h after treatment, and no gastrointestinal adverse events and abnormal bleeding were observed. No significant differences in the serum levels of IL-6 were found between the two groups at 12 and 24 h after treatment. Significantly lower serum levels of TXA2 and PGI2 were found in group A compared to group B at 12 and 24 h after treatment (P&#x0003c;0.05). Serum level of PGI2 was positively correlated with serum level of TXA2 (r=0.7212, P&#x0003c;0.05) and VAS score (r=0.7159, P&#x0003c;0.05). Serum level of IL-6 was positively correlated with VAS score (r=0.7997, P&#x0003c;0.05). The results show that flurbiprofen axetil can effectively relieve pain in patients with bone metastases of cancer, can inhibit platelet activation, adhesion and aggregation, and reduce the formation of deep vein thrombosis, and can inhibit stress response and inflammatory response in the body.</p></abstract><kwd-group><kwd>flurbiprofen</kwd><kwd>bone metastasis of cancer</kwd><kwd>interleukin-6</kwd><kwd>prostacyclin</kwd><kwd>corticosteroid A2</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Bone metastasis is the most common type of tumor metastasis in patients with advanced malignant tumors, and approximately 1.5 million patients were diagnosed with bone metastases of cancer each year (<xref rid="b1-ol-0-0-7482" ref-type="bibr">1</xref>). Cytokines secreted by tumor cells can disturb the dynamic balance between bone formation and bone dissolution, and can increase the bone dissolution rate, which in turn leads the occurrence of bone pain, bone marrow infiltration and other bone-related pathological changes in patients (<xref rid="b2-ol-0-0-7482" ref-type="bibr">2</xref>,<xref rid="b3-ol-0-0-7482" ref-type="bibr">3</xref>), affecting the quality of life and prognosis of patients.</p><p>Flurbiprofen axetil cannot only induce preemptive analgesia (<xref rid="b4-ol-0-0-7482" ref-type="bibr">4</xref>), but also can reduce inflammatory response during extubation. As an analgesic carrier, lurbiprofen axetil has the features of a non-selective and non-steroidal drug (<xref rid="b5-ol-0-0-7482" ref-type="bibr">5</xref>) and achieves a targeted effect. Analgesia can be easily induced and the analgesic effect can last for a long period of time. Flurbiprofen axetil achieves its analgesic effect by inhibiting epoxidase and reducing the uptake of prostaglandins by prostaglandin synthesis cells (<xref rid="b6-ol-0-0-7482" ref-type="bibr">6</xref>,<xref rid="b7-ol-0-0-7482" ref-type="bibr">7</xref>). Side effects of flurbiprofen axetil, such as central inhibition and gastrointestinal bleeding are relatively rare (<xref rid="b8-ol-0-0-7482" ref-type="bibr">8</xref>). As a defensive behavior of the body, stress response achieves its biological roles by regulating immune function and coagulation. Levels of stress hormones and immune factors are commonly used to assess the degree of stress response (<xref rid="b9-ol-0-0-7482" ref-type="bibr">9</xref>). The dynamic balance between inflammatory and anti-inflammatory factors plays a major role in postoperative inflammation. Postoperative complications are closely correlated with changes in immune function caused by surgical trauma and other stimuli (<xref rid="b10-ol-0-0-7482" ref-type="bibr">10</xref>).</p><p>Therefore, this study aimed to investigate the effects of flurbiprofen axetil on the serum levels of interleukin-6 (IL-6), prostacyclin (PGI2) and corticosteroid A2 (TXA2) in patients with malignant tumors with the expectation of identifying a novel method to reduce postoperative inflammatory and stress responses (<xref rid="b11-ol-0-0-7482" ref-type="bibr">11</xref>).</p></sec><sec sec-type="materials|methods"><title>Materials and methods</title><sec><title/><sec><title>Clinical data</title><p>A total of 210 patients with lung cancer were selected in The Affiliated Hospital of Qingdao University (Shandong, China) from January 2016 to December 2016. Patients were randomly divided into flurbiprofen axetil and dezocine group, 105 cases in each group.</p></sec><sec><title>Inclusion criteria</title><p>Inclusion criteria for the study were: i) Patients diagnosed with bone metastasis of lung cancer; ii) ASA (<xref rid="b12-ol-0-0-7482" ref-type="bibr">12</xref>) (American Association of Anesthesiologists) grade from I to II; iii) patients without liver, kidney and other organ dysfunction before surgery; iv) patients without abnormal bleeding or abnormal coagulation; v) patients who did not receive radiotherapy and chemotherapy before surgery; and vi) patients or their family members who signed informed consent.</p></sec><sec><title>Exclusion criteria</title><p>Exclusion criteria for the study were: i) Patients allergic to non-steroidal drug; ii) patients with a history of gastrointestinal ulcers or gastrointestinal bleeding; and iii) pregnant women or lactating women.</p></sec><sec><title>Intravenous infusion of flurbiprofen axetil or dezocine</title><p>Analgesia for patients in group A (flurbiprofen axetil group) was performed by intravenous infusion of flurbiprofen axetil (0.05 g), while intravenous infusion of dezocine (0.05 g) was performed for patients in group B (dezocine group).</p></sec><sec><title>Observation indicators</title><p>Visual analogue scale (VAS) scores at 1, 12, 24 and 48 h after surgery were recorded. Double-antibody sandwich enzyme-linked immunosorbent assay was used to detect erum levels of IL-6, PGI2 and TXA2 at 12 and 24 h after treatment.</p></sec><sec><title>Statistical analysis</title><p>SPSS 19 software (SPSS, Inc., Chicago, IL, USA) was used. Imitating normal distribution was performed by Student's t-test. P&#x0003c;0.05 was considered to indicate a statistically significant difference.</p></sec></sec></sec><sec sec-type="results"><title>Results</title><sec><title/><sec><title>Basic information</title><p>No significant differences in age, sex and temperature were found between the two groups of patients (P&#x0003e;0.05). Liver, renal and coagulation dysfunction were not found in patients. All the patients were found to be with normal levels of white blood cells (<xref rid="tI-ol-0-0-7482" ref-type="table">Table I</xref>). The patients were diagnosed with bone metastasis of lung cancer (<xref rid="tI-ol-0-0-7482" ref-type="table">Table I</xref>).</p></sec><sec><title>Comparison of VAS scores and serum levels of IL-6, TXA2 and PGI2 between the two groups</title><p>The VAS score was determined as previously established (<xref rid="b13-ol-0-0-7482" ref-type="bibr">13</xref>). No significant differences in VAS score were found between the two groups at 1, 12, 24 and 48 h after surgery (P&#x0003e;0.05) (<xref rid="tII-ol-0-0-7482" ref-type="table">Table II</xref>).</p><p>There was no significant difference in the serum level of IL-6 between the two groups at 12 and 24 h after surgery (P&#x0003e;0.05). Compared with the dezocine group, serum levels of PGI2 and TXA2 were significantly decreased in the flurbiprofen axetil group (P&#x0003c;0.05) (<xref rid="tIII-ol-0-0-7482" ref-type="table">Table III</xref>).</p><p>There was a positive correlation between the serum level of IL-6 and VAS score (r=0.7997, P&#x0003c;0.05). The serum level of PGI2 was positively correlated with the serum level of TXA2 (r=0.7212, P&#x0003c;0.05) and VAS score (r=0.7159, P&#x0003c;0.05) (<xref rid="tIV-ol-0-0-7482" ref-type="table">Table IV</xref>).</p></sec></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>Bone metastasis of cancer can disrupt the dynamic balance between bone formation and osteolysis, thus increasing the bone dissolution rate and affecting bone structure, which in turn induces bone pain, bone marrow infiltration and other bone-related pathological changes, leading to severe effects on the quality of life and prognosis of patients.</p><p>Flurbiprofen axetil is a non-selective and non-steroidal drug as an analgesic (<xref rid="b14-ol-0-0-7482" ref-type="bibr">14</xref>) that can achieve a targeting effect (<xref rid="b15-ol-0-0-7482" ref-type="bibr">15</xref>). Flurbiprofen axetil can be accumulated at the sites of injury and inflammation to inhibit the activity of cyclooxygenase (COX), which in turn achieves analgesic effect (<xref rid="b16-ol-0-0-7482" ref-type="bibr">16</xref>). In addition, flurbiprofen axetil can be absorbed by M&#x003c6; and Neu and other periglomerular (PG) cells to inhibit the synthesis and release of PG, thereby reducing tissue edema and inflammatory response caused by surgical trauma (<xref rid="b17-ol-0-0-7482" ref-type="bibr">17</xref>,<xref rid="b18-ol-0-0-7482" ref-type="bibr">18</xref>). Flurbiprofen axetil can inhibit stress response and reduce the pain caused by extubation after surgery (<xref rid="b17-ol-0-0-7482" ref-type="bibr">17</xref>,<xref rid="b18-ol-0-0-7482" ref-type="bibr">18</xref>).</p><p>PG can cause inflammatory response, promote vasodilation, increase permeability of the vascular wall and induce swelling and other clinical features (<xref rid="b19-ol-0-0-7482" ref-type="bibr">19</xref>). TXA2 is mainly secreted by platelet (PLT). TXA2 plays an essential role in PLT aggregation and vasoconstriction, and is a specific marker of PLT activation in the body. Flurbiprofen axetil can inhibit the activity of COX and promote the synthesis and release of IL-6 (<xref rid="b20-ol-0-0-7482" ref-type="bibr">20</xref>). This in turn, reduces stress response and enhances the analgesic effect of flurbiprofen axetil. Both pro- and anti-inflammatory factors are involved in the inflammatory response. Pro-inflammatory factors can induce inflammatory response, while anti-inflammatory factors can affect immune function.</p><p>Continuous intravenous infusion of non-selective cyclooxygenase inhibitors may inhibit platelet function, leading to postoperative bleeding in patients (<xref rid="b21-ol-0-0-7482" ref-type="bibr">21</xref>). Therefore, monitoring of coagulation function should be performed.</p><p>In the present study, no significant differences in VAS scores were found between the two groups at 1, 12, 24 and 48 h after surgery, indicating that flurbiprofen and dezocine have similar efficiencies in analgesia.</p><p>No significant differences in serum levels of IL-6 were found between the two groups at 12 and 24 h after surgery, indicating that flurbiprofen axetil has no specific effect on stress response. However, flurbiprofen axetil can still reduce stress response to a certain extent, which is inconsistent with the findings reported by Zhang <italic>et al</italic> (<xref rid="b22-ol-0-0-7482" ref-type="bibr">22</xref>). Zhang <italic>et al</italic> found no significant changes in PG after flurbiprofen axetil treatment, which may be explained by the different sample size and detection method (<xref rid="b22-ol-0-0-7482" ref-type="bibr">22</xref>). Serum levels of TXA2 and PGI2 were significantly lower in the flurbiprofen than in the dezocine group, indicating that flurbiprofen axetil can significantly affect the inflammatory response and blood coagulation. This finding is consistent with the results reported by Jiang <italic>et al</italic>, who found that flurbiprofen axetil can reduce the level of TXA2 (<xref rid="b23-ol-0-0-7482" ref-type="bibr">23</xref>). IL-6 level was positively correlated with VAS scores. PGI2 level in serum was positively correlated with serum level of TXA2 and VAS score. Clinicians can roughly estimate levels of IL-6 and PGI2 in patients according to VAS scores. In patients with bone metastases of lung cancer, there is a link between stress and inflammatory responses (<xref rid="b24-ol-0-0-7482" ref-type="bibr">24</xref>).</p><p>In conclusion, Flurbiprofen axetil can effectively relieve the pain of patients with bone metastases of lung cancer, can prevent thrombosis and promote blood flow, and can inhibit stress and inflammatory responses in the body.</p></sec></body><back><ref-list><title>References</title><ref id="b1-ol-0-0-7482"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Du</surname><given-names>S</given-names></name></person-group><article-title>Efficasy and safety of zoledronic acid and pamidronate disodium in the treatment of malignant skeletal metastasis: A meta-analysis</article-title><source>Medicine (Baltimore)</source><volume>94</volume><fpage>e1822</fpage><year>2015</year><pub-id pub-id-type="doi">10.1097/MD.0000000000001822</pub-id><pub-id pub-id-type="pmid">26496320</pub-id></element-citation></ref><ref id="b2-ol-0-0-7482"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silva</surname><given-names>SC</given-names></name><name><surname>Wilson</surname><given-names>C</given-names></name><name><surname>Woll</surname><given-names>PJ</given-names></name></person-group><article-title>Bone-targeted agents in the treatment of lung cancer</article-title><source>Ther Adv Med Oncol</source><volume>7</volume><fpage>219</fpage><lpage>228</lpage><year>2015</year><pub-id pub-id-type="doi">10.1177/1758834015582178</pub-id><pub-id pub-id-type="pmid">26136853</pub-id></element-citation></ref><ref id="b3-ol-0-0-7482"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winter</surname><given-names>MC</given-names></name><name><surname>Coleman</surname><given-names>RE</given-names></name></person-group><article-title>Bisphosphonates in the adjuvant treatment of breast cancer</article-title><source>Clin Oncol</source><volume>25</volume><fpage>135</fpage><lpage>145</lpage><year>2013</year><pub-id pub-id-type="doi">10.1016/j.clon.2012.10.010</pub-id></element-citation></ref><ref id="b4-ol-0-0-7482"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCormick</surname><given-names>Z</given-names></name><name><surname>Chang-Chien</surname><given-names>G</given-names></name><name><surname>Marshall</surname><given-names>B</given-names></name><name><surname>Huang</surname><given-names>M</given-names></name><name><surname>Harden</surname><given-names>RN</given-names></name></person-group><article-title>Phantom limb pain: A systematic neuroanatomical-based review of pharmacologic treatment</article-title><source>Pain Med</source><volume>15</volume><fpage>292</fpage><lpage>305</lpage><year>2014</year><pub-id pub-id-type="doi">10.1111/pme.12283</pub-id><pub-id pub-id-type="pmid">24224475</pub-id></element-citation></ref><ref id="b5-ol-0-0-7482"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kushwaha</surname><given-names>N</given-names></name><name><surname>Sahu</surname><given-names>S</given-names></name><name><surname>Tyagi</surname><given-names>RK</given-names></name></person-group><article-title>Flurbiprofen axetil loaded coaxial electrospun poly(vinyl pyrrolidone)-nanopoly(lactic-co-glycolic acid) core-shell composite nanofibers: Preparation, characterization, and anti-adhesion activity</article-title><source>J Appl Polym Sci</source><volume>132</volume><fpage>899</fpage><lpage>907</lpage><year>2015</year></element-citation></ref><ref id="b6-ol-0-0-7482"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Xing</surname><given-names>J</given-names></name><name><surname>Gao</surname><given-names>X</given-names></name><name><surname>Chang</surname><given-names>P</given-names></name><name><surname>Li</surname><given-names>W</given-names></name></person-group><article-title>Flurbiprofen axetil reduces postoperative sufentanil consumption and enhances postoperative analgesic effects in patients with colorectal cancer surgery</article-title><source>Int J Clin Exp Med</source><volume>7</volume><fpage>4887</fpage><lpage>4896</lpage><year>2014</year><pub-id pub-id-type="pmid">25663985</pub-id></element-citation></ref><ref id="b7-ol-0-0-7482"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wen</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>H</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Zhou</surname><given-names>Z</given-names></name><name><surname>Deng</surname><given-names>H</given-names></name><name><surname>Castillo-Pedraza</surname><given-names>C</given-names></name><etal/></person-group><article-title>A comparison of fentanyl and flurbiprofen axetil on serum VEGF-C, TNF-&#x003b1;, and IL-1&#x003b2; concentrations in women undergoing surgery for breast cancer</article-title><source>Pain Pract</source><volume>15</volume><fpage>530</fpage><lpage>537</lpage><year>2015</year><pub-id pub-id-type="doi">10.1111/papr.12206</pub-id><pub-id pub-id-type="pmid">24807396</pub-id></element-citation></ref><ref id="b8-ol-0-0-7482"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baid</surname><given-names>M</given-names></name><name><surname>Kar</surname><given-names>M</given-names></name><name><surname>De</surname><given-names>U</given-names></name><name><surname>Mukhopadhyay</surname><given-names>M</given-names></name></person-group><article-title>Conventional laparoscopic appendicectomy and laparoscope-assisted appendicectomy: A comparative study</article-title><source>Indian J Surg</source><volume>77</volume><fpage>330</fpage><lpage>334</lpage><year>2015</year><pub-id pub-id-type="doi">10.1007/s12262-013-0824-5</pub-id><pub-id pub-id-type="pmid">26730020</pub-id></element-citation></ref><ref id="b9-ol-0-0-7482"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schiavone</surname><given-names>S</given-names></name><name><surname>Trabace</surname><given-names>L</given-names></name></person-group><article-title>Redox dysregulation biomarkers: Clinical outcomes and pharmacological implications for psychosis</article-title><source>Front Psychiatry</source><volume>8</volume><fpage>203</fpage><year>2017</year><pub-id pub-id-type="doi">10.3389/fpsyt.2017.00203</pub-id><pub-id pub-id-type="pmid">29118723</pub-id></element-citation></ref><ref id="b10-ol-0-0-7482"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antoun</surname><given-names>M</given-names></name><name><surname>Edwards</surname><given-names>KM</given-names></name><name><surname>Sweeting</surname><given-names>J</given-names></name><name><surname>Ding</surname><given-names>D</given-names></name></person-group><article-title>The acute physiological stress response to driving: A systematic review</article-title><source>PLoS One</source><volume>12</volume><fpage>e0185517</fpage><year>2017</year><pub-id pub-id-type="doi">10.1371/journal.pone.0185517</pub-id><pub-id pub-id-type="pmid">29036199</pub-id></element-citation></ref><ref id="b11-ol-0-0-7482"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tabellini</surname><given-names>G</given-names></name><name><surname>Borsani</surname><given-names>E</given-names></name><name><surname>Benassi</surname><given-names>M</given-names></name><name><surname>Patrizi</surname><given-names>O</given-names></name><name><surname>Ricotta</surname><given-names>D</given-names></name><name><surname>Caimi</surname><given-names>L</given-names></name><name><surname>Lanzi</surname><given-names>R</given-names></name><name><surname>Micheli</surname><given-names>F</given-names></name><name><surname>Iorno</surname><given-names>V</given-names></name><name><surname>Bettaglio</surname><given-names>R</given-names></name><etal/></person-group><article-title>Effects of opioid therapy on human natural killer cells</article-title><source>Int Immunopharmacol</source><volume>18</volume><fpage>169</fpage><lpage>174</lpage><year>2014</year><pub-id pub-id-type="doi">10.1016/j.intimp.2013.11.015</pub-id><pub-id pub-id-type="pmid">24287448</pub-id></element-citation></ref><ref id="b12-ol-0-0-7482"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pillai</surname><given-names>AK</given-names></name><name><surname>Kovoor</surname><given-names>JM</given-names></name><name><surname>Reis</surname><given-names>SP</given-names></name><name><surname>Kho</surname><given-names>K</given-names></name><name><surname>Sutphin</surname><given-names>PD</given-names></name><name><surname>Lucas</surname><given-names>E</given-names></name></person-group><article-title>Expulsion of a uterine fibroid into the small bowel through uteroenteric fistula presenting with bowel obstruction after uterine fibroid embolization: Case report with histopathologic correlation</article-title><source>J Vasc Interv Radiol</source><volume>27</volume><fpage>762</fpage><lpage>764</lpage><year>2016</year><pub-id pub-id-type="doi">10.1016/j.jvir.2015.11.047</pub-id><pub-id pub-id-type="pmid">27106649</pub-id></element-citation></ref><ref id="b13-ol-0-0-7482"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>JC</given-names></name><name><surname>Sun</surname><given-names>HL</given-names></name><name><surname>Zhang</surname><given-names>MQ</given-names></name><name><surname>Liu</surname><given-names>XY</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>JJ</given-names></name></person-group><article-title>Flurbiprofen improves dysfunction of T-lymphocyte subsets and natural killer cells in cancer patients receiving post-operative morphine analgesia</article-title><source>Int J Clin Pharmacol Ther</source><volume>52</volume><fpage>669</fpage><lpage>675</lpage><year>2014</year><pub-id pub-id-type="doi">10.5414/CP202027</pub-id><pub-id pub-id-type="pmid">24755130</pub-id></element-citation></ref><ref id="b14-ol-0-0-7482"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Luo</surname><given-names>Z</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Shi</surname><given-names>H</given-names></name><etal/></person-group><article-title>Efficacy and safety of flurbiprofen axetil in the prevention of pain on propofol injection: A systematic review and meta-analysis</article-title><source>Med Sci Monit</source><volume>20</volume><fpage>995</fpage><lpage>1002</lpage><year>2014</year><pub-id pub-id-type="doi">10.12659/MSM.890102</pub-id><pub-id pub-id-type="pmid">24935068</pub-id></element-citation></ref><ref id="b15-ol-0-0-7482"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geng</surname><given-names>W</given-names></name><name><surname>Hong</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Dai</surname><given-names>Q</given-names></name><name><surname>Mo</surname><given-names>Y</given-names></name><name><surname>Shi</surname><given-names>K</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Qin</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Tang</surname><given-names>H</given-names></name></person-group><article-title>Flurbiprofen axetil enhances analgesic effects of sufentanil and attenuates postoperative emergence agitation and systemic proinflammation in patients undergoing tangential excision surgery</article-title><source>Mediators Inflamm</source><volume>2015</volume><fpage>601083</fpage><year>2015</year><pub-id pub-id-type="doi">10.1155/2015/601083</pub-id><pub-id pub-id-type="pmid">26273138</pub-id></element-citation></ref><ref id="b16-ol-0-0-7482"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>TT</given-names></name><name><surname>Wang</surname><given-names>ZG</given-names></name><name><surname>Ou</surname><given-names>WL</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Yao</surname><given-names>GQ</given-names></name><name><surname>Yang</surname><given-names>B</given-names></name><name><surname>Rao</surname><given-names>ZG</given-names></name><name><surname>Gao</surname><given-names>JF</given-names></name><name><surname>Zhang</surname><given-names>BC</given-names></name></person-group><article-title>Intravenous flurbiprofen axetil enhances analgesic effect of opioids in patients with refractory cancer pain by increasing plasma &#x003b2;-endorphin</article-title><source>Asian Pac J Cancer Prev</source><volume>15</volume><fpage>10855</fpage><lpage>10860</lpage><year>2014</year><pub-id pub-id-type="doi">10.7314/APJCP.2014.15.24.10855</pub-id><pub-id pub-id-type="pmid">25605189</pub-id></element-citation></ref><ref id="b17-ol-0-0-7482"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clancy</surname><given-names>NT</given-names></name><name><surname>Arya</surname><given-names>S</given-names></name><name><surname>Stoyanov</surname><given-names>D</given-names></name><name><surname>Singh</surname><given-names>M</given-names></name><name><surname>Hanna</surname><given-names>GB</given-names></name><name><surname>Elson</surname><given-names>DS</given-names></name></person-group><article-title>Intraoperative measurement of bowel oxygen saturation using a multispectral imaging laparoscope</article-title><source>Biomed Opt Express</source><volume>6</volume><fpage>4179</fpage><lpage>4190</lpage><year>2015</year><pub-id pub-id-type="doi">10.1364/BOE.6.004179</pub-id><pub-id pub-id-type="pmid">26504664</pub-id></element-citation></ref><ref id="b18-ol-0-0-7482"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>JC</given-names></name><name><surname>Sun</surname><given-names>HL</given-names></name><name><surname>Zhang</surname><given-names>MQ</given-names></name><name><surname>Liu</surname><given-names>XY</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>JJ</given-names></name></person-group><article-title>Flurbiprofen improves dysfunction of T-lymphocyte subsets and natural killer cells in cancer patients receiving post-operative morphine analgesia</article-title><source>Int J Clin Pharmacol Ther</source><volume>52</volume><fpage>669</fpage><lpage>675</lpage><year>2014</year><pub-id pub-id-type="doi">10.5414/CP202027</pub-id><pub-id pub-id-type="pmid">24755130</pub-id></element-citation></ref><ref id="b19-ol-0-0-7482"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Kong</surname><given-names>M</given-names></name></person-group><article-title>Effects of flurbiprofen axetil on postoperative analgesia and cytokines in peripheral blood of thoracotomy patients</article-title><source>Cell Biochem Biophys</source><volume>72</volume><fpage>429</fpage><lpage>432</lpage><year>2015</year><pub-id pub-id-type="doi">10.1007/s12013-014-0482-7</pub-id><pub-id pub-id-type="pmid">25608632</pub-id></element-citation></ref><ref id="b20-ol-0-0-7482"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Celik</surname><given-names>IH</given-names></name><name><surname>Demirel</surname><given-names>G</given-names></name><name><surname>Uras</surname><given-names>N</given-names></name><name><surname>Oguz</surname><given-names>ES</given-names></name><name><surname>Erdeve</surname><given-names>O</given-names></name><name><surname>Dilmen</surname><given-names>U</given-names></name></person-group><article-title>The role of serum interleukin-6 and C-reactive protein levels for differentiating aetiology of neonatal sepsis</article-title><source>Arch Argent Pediatr</source><volume>113</volume><fpage>534</fpage><lpage>537</lpage><year>2015</year><comment>(In Spanish)</comment><pub-id pub-id-type="pmid">26593799</pub-id></element-citation></ref><ref id="b21-ol-0-0-7482"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patricio</surname><given-names>JP</given-names></name><name><surname>Barbosa</surname><given-names>JP</given-names></name><name><surname>Ramos</surname><given-names>RM</given-names></name><name><surname>Antunes</surname><given-names>NF</given-names></name><name><surname>de Melo</surname><given-names>PC</given-names></name></person-group><article-title>Relative cardiovascular and gastrointestinal safety of non-selective non-steroidal anti-inflammatory drugs versus cyclo-oxygenase-2 inhibitors: Implications for clinical practice</article-title><source>Clin Drug Investig</source><volume>33</volume><fpage>167</fpage><lpage>183</lpage><year>2013</year><pub-id pub-id-type="doi">10.1007/s40261-013-0052-6</pub-id><pub-id pub-id-type="pmid">23338974</pub-id></element-citation></ref><ref id="b22-ol-0-0-7482"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Shu</surname><given-names>R</given-names></name><name><surname>Zhao</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name></person-group><article-title>Preoperative but not postoperative flurbiprofen axetil alleviates remifentanil-induced hyperalgesia after laparoscopic gynecological surgery: A prospective, randomized, double-blinded, trial</article-title><source>Clin J Pain</source><volume>33</volume><fpage>435</fpage><lpage>442</lpage><year>2017</year><pub-id pub-id-type="doi">10.1097/AJP.0000000000000416</pub-id><pub-id pub-id-type="pmid">27518488</pub-id></element-citation></ref><ref id="b23-ol-0-0-7482"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>WW</given-names></name><name><surname>Wang</surname><given-names>QH</given-names></name><name><surname>Peng</surname><given-names>P</given-names></name><name><surname>Liao</surname><given-names>YJ</given-names></name><name><surname>Duan</surname><given-names>HX</given-names></name><name><surname>Xu</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>PB</given-names></name></person-group><article-title>Effects of flurbiprofen axetil on postoperative serum IL-2 and IL-6 levels in patients with colorectal cancer</article-title><source>Genet Mol Res</source><volume>14</volume><fpage>16469</fpage><lpage>16475</lpage><year>2015</year><pub-id pub-id-type="doi">10.4238/2015.December.9.18</pub-id><pub-id pub-id-type="pmid">26662445</pub-id></element-citation></ref><ref id="b24-ol-0-0-7482"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Gong</surname><given-names>Z</given-names></name></person-group><article-title>Clinical characteristics and prognostic factors in bone metastases from lung cancer</article-title><source>Med Sci Monit</source><volume>23</volume><fpage>4087</fpage><lpage>4094</lpage><year>2017</year><pub-id pub-id-type="doi">10.12659/MSM.902971</pub-id><pub-id pub-id-type="pmid">28835603</pub-id></element-citation></ref></ref-list></back><floats-group><table-wrap id="tI-ol-0-0-7482" orientation="portrait" position="float"><label>Table I.</label><caption><p>Comparison of basic information between the two groups.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Variables</th><th align="center" valign="bottom" rowspan="1" colspan="1">Flurbiprofenaxetil group n=105</th><th align="center" valign="bottom" rowspan="1" colspan="1">Dezocine group n=105</th><th align="center" valign="bottom" rowspan="1" colspan="1">P-value</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Age (years)</td><td align="center" valign="top" rowspan="1" colspan="1">60&#x000b1;5.3</td><td align="center" valign="top" rowspan="1" colspan="1">56&#x000b1;4.7</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003e;0.05</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sex (male/female)</td><td align="center" valign="top" rowspan="1" colspan="1">53/52</td><td align="center" valign="top" rowspan="1" colspan="1">49/56</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003e;0.05</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Temperature</td><td align="center" valign="top" rowspan="1" colspan="1">37.62&#x000b1;0.57</td><td align="center" valign="top" rowspan="1" colspan="1">37.82&#x000b1;0.63</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003e;0.05</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Alanine aminotransferase</td><td align="center" valign="top" rowspan="1" colspan="1">36.12&#x000b1;26.89</td><td align="center" valign="top" rowspan="1" colspan="1">36.25&#x000b1;27.13</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003e;0.05</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Creatinine</td><td align="center" valign="top" rowspan="1" colspan="1">24.39&#x000b1;6.79</td><td align="center" valign="top" rowspan="1" colspan="1">22.33&#x000b1;6.31</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003e;0.05</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">White blood cell count</td><td align="center" valign="top" rowspan="1" colspan="1">9.59&#x000b1;3.71</td><td align="center" valign="top" rowspan="1" colspan="1">9.88&#x000b1;3.99</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003e;0.05</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Platelet count</td><td align="center" valign="top" rowspan="1" colspan="1">133&#x000b1;10.32</td><td align="center" valign="top" rowspan="1" colspan="1">152&#x000b1;11.49</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003e;0.05</td></tr></tbody></table></table-wrap><table-wrap id="tII-ol-0-0-7482" orientation="portrait" position="float"><label>Table II.</label><caption><p>Comparison of VAS scores between the two groups.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Time</th><th align="center" valign="bottom" rowspan="1" colspan="1">Group A</th><th align="center" valign="bottom" rowspan="1" colspan="1">Group B</th><th align="center" valign="bottom" rowspan="1" colspan="1">t-value</th><th align="center" valign="bottom" rowspan="1" colspan="1">P-value</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">1 h</td><td align="center" valign="top" rowspan="1" colspan="1">5.3&#x000b1;0.4</td><td align="center" valign="top" rowspan="1" colspan="1">6.1&#x000b1;0.5</td><td align="center" valign="top" rowspan="1" colspan="1">4.13</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003e;0.05</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">12 h</td><td align="center" valign="top" rowspan="1" colspan="1">5.1&#x000b1;0.6</td><td align="center" valign="top" rowspan="1" colspan="1">5.9&#x000b1;0.4</td><td align="center" valign="top" rowspan="1" colspan="1">3.79</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003e;0.05</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">24 h</td><td align="center" valign="top" rowspan="1" colspan="1">4.8&#x000b1;0.4</td><td align="center" valign="top" rowspan="1" colspan="1">5.4&#x000b1;0.5</td><td align="center" valign="top" rowspan="1" colspan="1">4.21</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003e;0.05</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">48 h</td><td align="center" valign="top" rowspan="1" colspan="1">4.4&#x000b1;0.8</td><td align="center" valign="top" rowspan="1" colspan="1">4.9&#x000b1;0.3</td><td align="center" valign="top" rowspan="1" colspan="1">4.89</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003e;0.05</td></tr></tbody></table><table-wrap-foot><fn id="tfn1-ol-0-0-7482"><p>VAS, visual analogue scale.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tIII-ol-0-0-7482" orientation="portrait" position="float"><label>Table III.</label><caption><p>Comparison of serum levels of IL-6, TXA2 and PGI2 between the two groups.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th align="center" valign="bottom" colspan="2" rowspan="1">Groups</th><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/></tr><tr><th rowspan="1" colspan="1"/><th align="center" valign="bottom" colspan="2" rowspan="1"><hr/></th><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/></tr><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Variables</th><th align="center" valign="bottom" rowspan="1" colspan="1">A</th><th align="center" valign="bottom" rowspan="1" colspan="1">B</th><th align="center" valign="bottom" rowspan="1" colspan="1">t-value</th><th align="center" valign="bottom" rowspan="1" colspan="1">P-value</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">IL-6</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;12 h</td><td align="center" valign="top" rowspan="1" colspan="1">73.92&#x000b1;7.21</td><td align="center" valign="top" rowspan="1" colspan="1">78.81&#x000b1;9.24</td><td align="center" valign="top" rowspan="1" colspan="1">0.16</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003e;0.05</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;24 h</td><td align="center" valign="top" rowspan="1" colspan="1">68.83&#x000b1;6.93</td><td align="center" valign="top" rowspan="1" colspan="1">72.56&#x000b1;8.39</td><td align="center" valign="top" rowspan="1" colspan="1">0.24</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003e;0.05</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">TXA2</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;12 h</td><td align="center" valign="top" rowspan="1" colspan="1">52.82&#x000b1;7.31</td><td align="center" valign="top" rowspan="1" colspan="1">88.52&#x000b1;8.72</td><td align="center" valign="top" rowspan="1" colspan="1">5.27</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;0.05</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;24 h</td><td align="center" valign="top" rowspan="1" colspan="1">44.43&#x000b1;6.8</td><td align="center" valign="top" rowspan="1" colspan="1">78.64&#x000b1;7.98</td><td align="center" valign="top" rowspan="1" colspan="1">5.39</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;0.05</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PGI2</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;12 h</td><td align="center" valign="top" rowspan="1" colspan="1">47.15&#x000b1;6.68</td><td align="center" valign="top" rowspan="1" colspan="1">79.24&#x000b1;5.87</td><td align="center" valign="top" rowspan="1" colspan="1">6.03</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;0.05</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;24 h</td><td align="center" valign="top" rowspan="1" colspan="1">40.26&#x000b1;5.79</td><td align="center" valign="top" rowspan="1" colspan="1">75.41&#x000b1;6.03</td><td align="center" valign="top" rowspan="1" colspan="1">6.11</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;0.05</td></tr></tbody></table><table-wrap-foot><fn id="tfn2-ol-0-0-7482"><p>PGI2, prostacyclin; IL-6, interleukin-6; TXA2, corticosteroid A2.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tIV-ol-0-0-7482" orientation="portrait" position="float"><label>Table IV.</label><caption><p>Correlation between VAS score and serum levels of IL-6, TXA2 and PGI2 (r-value).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1">r-value</th><th align="center" valign="bottom" rowspan="1" colspan="1">VAS score</th><th align="center" valign="bottom" rowspan="1" colspan="1">IL-6</th><th align="center" valign="bottom" rowspan="1" colspan="1">TXA2</th><th align="center" valign="bottom" rowspan="1" colspan="1">PGI2</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">VAS score</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="top" rowspan="1" colspan="1">r=0.7997</td><td align="center" valign="top" rowspan="1" colspan="1">0.2145</td><td align="center" valign="top" rowspan="1" colspan="1">0.7159</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">IL-6</td><td align="center" valign="top" rowspan="1" colspan="1">0.7997</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="top" rowspan="1" colspan="1">0.1978</td><td align="center" valign="top" rowspan="1" colspan="1">0.2239</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">TXA2</td><td align="center" valign="top" rowspan="1" colspan="1">0.2145</td><td align="center" valign="top" rowspan="1" colspan="1">0.1978</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="top" rowspan="1" colspan="1">0.7212</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PGI2</td><td align="center" valign="top" rowspan="1" colspan="1">0.7159</td><td align="center" valign="top" rowspan="1" colspan="1">0.2239</td><td align="center" valign="top" rowspan="1" colspan="1">0.7212</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02013;</td></tr></tbody></table><table-wrap-foot><fn id="tfn3-ol-0-0-7482"><p>VAS, visual analogue scale; IL-6, interleukin-6; TXA2, corticosteroid A2; PGI2, prostacyclin.</p></fn></table-wrap-foot></table-wrap></floats-group></article>